| TA148 |
Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148) |
|
-
-
Bevacizumab for the treatment of non-small-cell lung cancer
NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.
-
Other information
How this guidance was produced
Background information
- None found
This page was last updated: 30 March 2010
-
-
Guidance formats
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
